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Abstract. A substantial body of evidence supports the hypothesis of a vascular component in the pathogenesis of Alzheimer’s
disease (AD). Cerebral hypoperfusion and blood-brain barrier dysfunction have been indicated as key elements of this path-
way. Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder, frequent in AD, characterized by the accumulation of
amyloid- (A) peptide in cerebral blood vessel walls. CAA is associated with loss of vascular integrity, resulting in impaired
regulation of cerebral circulation, and increased susceptibility to cerebral ischemia, microhemorrhages, and white matter dam-
age. Vasomotion—the spontaneous rhythmic modulation of arterial diameter, typically observed in arteries/arterioles in various
vascular beds including the brain—is thought to participate in tissue perfusion and oxygen delivery regulation. Vasomotion is
impaired in adverse conditions such as hypoperfusion and hypoxia. The perivascular and glymphatic pathways of A clearance
are thought to be driven by the systolic pulse. Vasomotion produces diameter changes of comparable amplitude, however at
lower rates, and could contribute to these mechanisms of A clearance. In spite of potential clinical interest, studies address-
ing cerebral vasomotion in the context of AD/CAA are limited. This study reviews the current literature on vasomotion, and
hypothesizes potential paths implicating impaired cerebral vasomotion in AD/CAA. A and oxidative stress cause vascular tone
dysregulation through direct effects on vascular cells, and indirect effects mediated by impaired neurovascular coupling. Vascular
tone dysregulation is further aggravated by cholinergic deficit and results in depressed cerebrovascular reactivity and (possibly)
impaired vasomotion, aggravating regional hypoperfusion and promoting further A and oxidative stress accumulation.
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INTRODUCTION
Neurovascular homeostasis in the brain is main-
tained through the inherent ability of vascular
resistance to adapt to changes in blood pressure,
thereby preserving an adequate and stable cerebral
blood flow (CBF) [1]. This adaptation mechanism,
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termed autoregulation, is essential as the brain has a
high metabolic demand.
Cerebral autoregulation is the outcome of a complex
interplay of vascular, neuronal, and metabolic compo-
nents, in which the vascular tonic response to increased
blood pressure (known as myogenic response [2])
plays an important role in maintaining an adequate
level of tissue perfusion.
Arterial resistance, especially in the arteriolar
circulation, is also modulated by spontaneous rhyth-
mic variations in the vessel lumen resulting from
smooth muscle dilatation and constriction. This intrin-
sic phenomenon, known as vasomotion [3–5], is
unrelated to cardiac rhythm, and is observed clin-
ically through related flow variations (flowmotion)
using non-invasive technologies such as laser Doppler
flowmetry.
Vasomotion has been observed in vitro and in vivo in
various vascular beds including, among others, skele-
tal muscles, cutaneous and retinal circulation, coronary
and mesenteric arteries [3, 5], and cerebral arteries
[6–8].
Despite research efforts spanning over 150 years,
both the underlying mechanisms and the functional
implications of vasomotion remain to some extent
unclear.
It has been suggested that vasomotion can improve
perfusion [9, 10] and local tissue oxygenation [11, 12].
Although experimental evidence is currently limited,
mathematical computational models also support the
role of vasomotion in oxygen (O2) delivery [13–15].
In the current view, vasomotion is the outcome of
multiple and interacting systems, in which the inhibi-
tion of one may unveil the role of another [5], thus
explaining the heterogeneous manifestation of vaso-
motion in different vascular beds within the same
organism. This heterogeneous distribution may repre-
sent an adaptation mechanism to meet the dynamically
changing local metabolic demand of the perfused tis-
sues [6, 16, 17].
Impaired cerebral autoregulation in Alzheimer’s
disease and cerebral amyloid angiopathy
Alzheimer’s disease
Alzheimer’s disease (AD) is the most prevalent
cause of dementia in the older population account-
ing for 65–70% of the cases [18–20]. The formation
of amyloid- (A) plaques and neurofibrillary tangles
are the hallmarks of AD [21]; however, autopsy stud-
ies also show symptoms of vascular pathology in the
majority of AD cases [22–25].
The mechanisms underlying AD pathogenesis are
not fully understood; however, a substantial body of
evidence supports the hypothesis of a vascular contri-
bution to pathophysiology [26–29], in which cerebral
hypoperfusion and blood-brain barrier dysfunction are
key elements [22, 26], aggravated by impaired cerebral
microcirculation [30, 31].
Cerebral autoregulation deteriorates with age
[32–34], increasing neuronal vulnerability to hypoxia
and ischemia [32]. In transgenic mice overexpressing
amyloid- protein precursor, impaired endothelium-
dependent vasodilatation and paradoxical vasocon-
striction reduce basal CBF [35], resulting in impaired
autoregulation [36]. In contrast with animal models,
preliminary data from AD patients show no alter-
ations of cerebral autoregulation [37]. These reports,
however, are currently few and based on very small
cohorts [38–40]. Furthermore, they rely on trans-
cranial Doppler (TCD) techniques for noninvasive
quantification of CBF (in the middle cerebral artery).
These techniques measure relative velocity instead of
absolute flow, under the assumption of constant arte-
rial diameter. On the other hand, imaging techniques
such as single-photon emission computed tomography
(SPECT), have provided evidence of cerebrovascu-
lar deficit with reduced regional CBF in AD patients
[41–44].
Cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA), a cerebrovas-
cular disorder characterized by the accumulation of A
peptide in the tunica media and adventitia of cerebral
blood vessels, is associated with vascular smooth mus-
cle cell degeneration and loss of vessel wall integrity
[45], resulting in impaired regulation of cerebral cir-
culation [46–50], vascular insufficiency and increased
susceptibility to cerebral ischemia [51], microhemor-
rhages [52], and white matter damage [51].
CAA is found in elderly patients without dementia;
however, its prevalence significantly increases in spo-
radic AD [23, 49], in which it is found in more than
60% of the cases [53]. CAA has been suggested to
damage the contractile apparatus of cerebral vessels,
and disrupt autoregulation [31].
Focus questions
Although vasomotion is thought to play an impor-
tant role in cerebral autoregulation, specific studies
in the context of AD or CAA in humans are
limited—possibly owing to the experimental complex-
ity of quantitative measurements. Furthermore, while
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experimental techniques for in vivo measurement of
vasomotion in animals are available, their application
to animal models of AD or CAA remains largely unex-
plored.
This study reviews the current literature on vasomo-
tion, in the attempt to address two questions:
Question I: “Is impaired vasomotion in cerebral
arteries implicated in the development or progression
of sporadic Alzheimer’s disease?”
This question is motivated by the current view
according to which vasomotion contributes to the reg-
ulation of tissue perfusion and O2 delivery [9–12].
Vasomotion can manifest as regular, rhythmic oscil-
lations or chaotic fluctuations [3, 54]. Chaotic patterns
in vasomotion have been suggested to reflect failure of
vascular tone regulation, resulting in inadequate blood
supply to the tissues [17].
Increasing incidence and magnitude of vasomotion
have been observed during acute conditions associated
with hypoxia [55], low blood pressure and hypoperfu-
sion [4, 56, 57], suggesting that vasomotion may play
a protective role in the attempt to preserve homeostasis
in acute conditions.
However, in chronic conditions such as diabetes
[58–61], obesity [5, 16], and hypertension [62, 63],
vasomotion appears to be depressed. Reports from
longitudinal studies suggest that diabetes [64–66],
untreated hypertension [67], and obesity at midlife
[68–70], are associated with an increased risk of devel-
oping AD, supporting the hypothesis of an indirect
link between depressed vasomotion and AD. How-
ever, the association between the above risk factors and
AD remains controversial as other longitudinal studies
have reported contrasting results [71–74].
Question II: “Does impaired vasomotion hinder
waste product drainage in Alzheimer’s disease?”
In spite of the high metabolic rate and sensitivity of
brain parenchymal cells to alterations in the extracellu-
lar environment, the brain lacks lymphatic vessels for
interstitial solute and fluid clearance [75], suggesting
an alternative pathway should exist.
Although the underlying mechanisms remain to
some extent unclear, two hypotheses on waste product
clearance in the brain have been proposed.
Observations using in vivo two-photon imaging
suggest that the cerebrospinal fluid from the subarach-
noid space enters the brain parenchyma following
para-arterial influx routes in the Virchow-Robin space
surrounding the penetrating cerebral arteries [75, 76].
The resulting interaction with the brain interstitial
fluid then acts to facilitate the clearance of intersti-
tial solutes (including A) via the paravascular spaces
surrounding large draining veins. This mechanism has
been reported to depend on the expression of water
channel aquaporin-4 in astrocytes [75]. Owing to its
functional analogy to peripheral lymph vessels, this
pathway has been termed “glymphatic” system [75].
A contrasting view suggests that the interstitial
solutes (including A) from the perivascular space
enter the basement membranes of capillaries and drain
along the basement membrane of the arterial tunica
media toward the leptomeningeal arteries, in opposite
direction to blood flow [77–80].
The driving force of this pathway would be the
reflected wave of systolic pulsations, assisted by a
“valve effect” of proteins in the basement membrane
[77]. These proteins, however, have not been identified.
In spite of the different drainage pathways, the two
above hypotheses share the common view of arterial
pulsation as driving force. The question then arises,
whether vasomotion could contribute to such force.
The rhythmic oscillations of vasomotion have com-
parable amplitude to those caused by the systolic
pulsation, in spite of the lower rate (1–20 cycles/min
[3, 4, 81–83]). In rat basilar arteries [82], the amplitude
of vasomotion (percentage diameter change) was 19%,
with a baseline diameter of 259 m.
The amplitude of systolic pulsations in the common
carotid artery of the adult mouse brain is calculated to
12% according to [84, 85] (Table 1 in [84], for wild
type mice; assuming a baseline diameter of 400 m
[84, 85]).
This suggests that vasomotion could contribute to
the driving force of perivascular drainage of extracel-
lular fluids.
VASOMOTION
Mechanisms underlying vasomotion in cerebral
arteries
The ongoing debate on the mechanisms underly-
ing vasomotion reflects the inherent complexity of
this phenomenon, which involves interacting processes
that are difficult to target experimentally [86].
However, it is accepted that vasomotion is initi-
ated when asynchronous oscillations (waves) in Ca2+
concentration ([Ca2+]i) within vascular smooth mus-
cle cells become synchronized along the vascular wall
[5, 6].
A substantial body of evidence has consistently
shown in vitro that vasomotion is associated with oscil-
lations in the membrane potential of vascular smooth
muscle cells [86–91].
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The voltage-dependent cell membrane oscillator
Experimental data from rat basilar arteries sup-
port the hypothesis of a voltage-dependent membrane
oscillator [6]. According to this model, the smooth
muscle cell membrane undergoes cyclic depolarization
and hyperpolarization stages, associated with open-
ing and closing of Ca2+-dependent chloride channels
(ClCa) and intermediate conductance potassium chan-
nels (IKCa), respectively.
Phase I: Vascular smooth muscle cell
depolarization
Inositol 1,4,5-trisphosphate (IP3), produced by
phospholipase C (PLC), leads to Ca2+ release through
IP3 receptors from the sarcoplasmic reticulum (SR).
Increased cytosolic Ca2+ concentration then activates
Ca2+-dependent chloride channels (ClCa), depolar-
izing the membrane and opening voltage-dependent
Ca2+ channel to extracellular Ca2+ influx [6]. This
activates ryanodine receptors resulting in further Ca2+
release into the cytosol, in a Ca2+-induced Ca2+
release fashion [7].
Phase II: Vascular smooth muscle cell
hyperpolarization
The increased [Ca2+]i opens IKCa channels result-
ing in membrane hyperpolarization, and subsequent
closing of voltage-dependent Ca2+ channels and
vasodilatation [7].
Following the increase in phase I, [Ca2+]i decreases
again as a result of two cooperating mechanisms: a
decreased Ca2+ release by the SR (possibly caused by
transient refractoriness to IP3) and the active removal
of Ca2+ from the cytosol, through SR and plasmalem-
mal Ca2+-ATPases [86].
The loss of activation of ryanodine-sensitive stores
then causes IKCa channels to close, completing the
cycle [7].
Role of the endothelium in vasomotion
The oscillating membrane potential of vascular
smooth muscle cells synchronizes [Ca2+]i oscilla-
tions of adjacent cells through endothelium-mediated
electrical coupling, via myoendothelial gap junctions
[6–8]. As membrane potential oscillations in endothe-
lial and smooth muscle cells were found to precede
the rhythmic contraction of the vessel wall, it was
suggested that the endothelium might initiate the syn-
chronized vasomotion [7].
A substantial body of evidence from in vitro stud-
ies suggests that, in cerebral arteries, endothelial nitric
oxide (NO) plays a role in the regulation of vasomo-
tion. In particular, inhibition of NO-synthesis has been
consistently reported to promote vasomotion [8, 17,
92–95].In [92], NO-synthase inhibitor Nω-nitro-L-
arginine (L-NA) induced cyclic variations of cortical
CBF in anesthetized rats. Consistent results were
obtained in [17] by blocking basal NO release with
L-NA. Exposure to NO inhibitor N-nitro-L-arginine
methyl ester also evoked vasomotion [8, 93, 94].
In non-cerebral vascular beds, the role of the
endothelium is less clear, with different and some-
times conflicting results. For example, removal of the
endothelium or blockade of NO production prevented
vasomotion in the hamster aorta [96], rat mesenteric
arteries [88, 90, 97], rabbit mesenteric [98, 99], and
coronary arteries [99], and also in the human cutaneous
circulation [100], whereas vasomotion was initiated
upon inhibition of endothelial NO in the hamster cheek
pouch [101], and rat mesenteric artery [102]. Other
studies have reported the absence of any endothelium-
mediated effects on vasomotion in the rat thoracic aorta
[103], rabbit mesenteric arteries [98], and pig coronary
arteries [104].
Neurovascular coupling in vascular tone
regulation and vasomotion
Astrocytes and the regulation of vascular tone
Mounting evidence from in vitro studies on animal
brain slices suggest that astrocytes may participate in
cerebral vascular tone regulation [105].
Astrocytes have indeed been shown to synthe-
size and release vasoactive agents such as NO,
prostaglandins, epoxyeicosatrienoic acids (EETs), glu-
tamate, adenosine and adenosine triphosphate (ATP)
[106, 107], which are potential mediators of vascular
tone regulation. The hypothesis of astrocyte involve-
ment is further supported by the anatomy, as astrocytes
are ideally situated in apposition to cerebral arteri-
oles and capillaries, which would facilitate the relay
of vasoactive signals [105].
Although studies on brain slices are limited by the
inherent absence of cerebral perfusion, which implies
the lack of myogenic and shear stress-induced modula-
tion of vascular tone [108, 109], they provide evidence
that Ca2+-related events in perivascular astrocytes can
influence vascular tone.
Conflicting results were reported by the early stud-
ies regarding the vascular response to astrocytic Ca2+
elevations such as induced by neuronal stimulation,
metabotropic glutamate receptor (mGluR) stimulation,
or direct Ca2+ uncaging—a technique based on local
release of Ca2+ from an inert molecule exposed to UV
photons [110, 111].
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In [112], vascular constrictions were observed when
uncaging-evoked Ca2+ waves propagated to the astro-
cyte end-feet and caused large increases in [Ca2+]i.
The authors postulated that increased [Ca2+]i in the
astrocyte end-feet could activate phospholipase A2 and
increase arachidonic acid (AA) formation. AA would
then diffuse to smooth muscle cells where it would
be converted to 20-hydroxyeicosatetraenoic acid by
CYP4A, a cytochrome P450 (CYP450) enzyme sub-
type, causing vasoconstriction. Contrasting results,
however, have been reported by other studies in
which vasodilatation rather than vasoconstriction was
observed [113–115], suggesting that the build-up of
AA in astrocytes could increase the production of
prostaglandins and EETs, causing parenchymal arte-
rioles to dilate [116].
Subsequent studies have reconciled these con-
flicting findings, suggesting that the polarity of
vascular responses (vasoconstriction versus vasodi-
latation) could depend on basal conditions such as
resting arteriolar tone [117], O2 concentration levels
[118], and NO availability [119]. The level of astro-
cytic increase of [Ca2+]i following stimulation has also
been suggested to play a role [120].
In [117], astrocytic stimulation by mGluR ago-
nist trans-1-aminocyclopentane-1,3-dicarboxylic acid
(t-ACPD) induced vasoconstriction in arterioles with
moderate basal tone (diameter greater than 70% of
maximum), and vasodilatation in arterioles with higher
basal tone. In [118], t-ACPD stimulation caused arte-
riolar dilatation in conditions of low O2 concentration
(20%) and arteriolar constriction at high O2 concentra-
tion (95%). Vasodilatation under low O2 was shown
to depend on enhanced lactate release by activated
astrocytes and increased extracellular levels of the
vasodilating agent prostaglandin E2. The authors also
observed increased extracellular levels of adenosine in
low O2 and suggested this might act upon A2A recep-
tors in smooth muscle cells to reduce Ca2+ channel
activity and inhibit contraction.
In [119], astrocyte-induced vasoconstriction was
attributed to NO interactions with AA metabolites due
to NO-mediated inhibition of CYP450 and the subse-
quent decrease in the formation of vasodilating EET.
In [120], the level of astrocyte end-feet Ca2+
determined the polarity of arteriolar response, with
increasing values shifting the vascular tone response
from vasodilatation to vasoconstriction. The response
was attributed to the activation of Ca2+-activated large
conductance K+ channels (BK) by the increased Ca2+
concentration, which caused extracellular K+ increase.
This, in turn caused vasodilatation at physiological
concentration levels (3 mM), and vasoconstriction at
higher concentrations (8 mM).
Astrocytes mediate functional hyperemia and
suppression of vasomotion
Astrocytes have been proposed to mediate vasodi-
latation of parenchymal arterioles in response to
increased neuronal activity. This mechanism, termed
‘functional hyperemia’, increases O2 and glucose sup-
ply to the active neurons in a timely and spatially
localized manner [106, 116].
In [106], increased neuronal activity by electrical
stimulation, increased astrocytic [Ca2+]i, and evoked
Ca2+ waves travelling from the soma towards the end-
foot. The increased Ca2+ in astrocytes was rapidly
signaled to the surrounding parenchymal arterioles,
which had been pre-constricted with thromboxane
A2 (TXA2) agonist U46619, where it suppressed
[Ca2+]i oscillations and vasomotion. Consistent with
the above, the same study also found that the acti-
vation of astrocytic glutamate receptors, which is
known to increase [Ca2+]i in cortical astrocytes
[121], had similar effects. Consistent findings have
been reported also in [122] and [123] using similar
preparations.
Furthermore, in [123] epoxygenase inhibitor
miconazole caused arteriolar vasoconstriction and
increased vasomotion oscillation frequency, suggest-
ing that EETs may act as mediators of neuronal-
activity-related dilatation of parenchymal arterioles
and dampening of vasomotion.
CAA and vasomotion
In CAA, A interacts predominantly with vascu-
lar smooth muscle cells in the tunica media causing
structural alterations such as the disruption of actin in
the cytoskeleton, and apoptosis [124–126]. The loss of
vascular smooth muscle cells with disease progression
weakens the vascular wall [127–129], increasing the
susceptibility to abnormal vasodilatation and hemor-
rhage [126, 130, 131].
A deposition also affects the luminal area of arte-
rial vessels. However, experimental data are conflicting
as both increase [127, 129] and decrease [128] of the
internal lumen have been reported. In the former case,
which is also supported by transgenic mouse studies
[130], vessel dilation could reduce the vascular reactiv-
ity to vasodilatory stimuli such as ischemia [126, 132]
or hypercapnia [133] (see section on cerebrovascular
reactivity). In the latter case, vasoconstriction could
result in hypoperfusion downstream of the narrowing
of the vascular lumen [126].
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However, while the experimental evidence
described above can be seen as the long-term out-
come, in the short-term other processes could take
place, with detrimental effects on vasomotion at an
early stage.
Indeed, vascular smooth muscle cells treated with
A1-40—the most frequent form of A in spo-
radic CAA—exhibit higher inflammatory response to
interleukin-1 [134]. This cytokine is expressed by
endothelial cells exposed to A1-40 [135]. As endothe-
lial cells are adjacent to smooth muscle cells, the above
finding suggests that A could mediate the inflamma-
tory response of smooth muscle cells, leading to the
loss of contractile function through the disruption of
-actin in the cytoskeleton [134].
Findings from in vitro studies on neuronal cells
suggest that the detrimental effects of A could also
impair intracellular Ca2+ dynamics as well as the
membrane potential [136, 137], resulting in the loss
of synchronization of cytosolic Ca2+ waves, a pre-
requisite of vasomotion according to the membrane
oscillator model [6].
The effect of oxidative stress
Oxidative stress has been implicated in AD and
CAA from the early stages of the disease [24, 49,
138–140]. As this condition is associated with mito-
chondrial dysfunction [138, 141, 142], which results
in ATP deficiency, it seems plausible that in AD/CAA,
ATP-dependent transport might be impaired not only
in neurons but also in vascular smooth muscle cells,
resulting in altered Ca2+ homeostasis and disruption
of vasomotion.
Vascular tortuosity and vasomotion
The long path of arterioles supplying the deep white
matter tends to become tortuous with aging [33, 143,
144]. Tortuosity manifests in the form of turns and curls
requiring increased perfusion pressure to maintain sta-
ble CBF [33]. It has been suggested that decreased
pulsations in tortuous vessels may impede intersti-
tial fluid flow, reducing A clearance in perivascular
spaces [143]. Although this suggests a potential impli-
cation of increased tortuosity in AD, existing reports
are inconclusive [144, 145].
In tortuous arterial vessels, vasomotion could act as a
protective mechanism by cooperating with the systolic
pulse in the attempt to compensate the dispersion of
kinetic energy of blood flow caused by turns and curls,
and preserve adequate CBF.
Disturbed blood flow such as occurring at turns and
loops of tortuous vessels is known to reduce the wall
shear stress exerted by blood flow [146–148]. On the
other hand, reduced wall shear stress is associated with
reduced endothelial NO production [149], a condition
which has been shown in vitro to promote vasomotion
[8, 17, 92–95]. This further supports the hypothesis of
a potential protective role of vasomotion in the pres-
ence of tortuous arteriolar paths. However, given the
intrinsic difficulty in measuring vasomotion in condi-
tions of tortuous blood flow in vivo, this hypothesis has
not been tested.
Temporal variability of vasomotion
The changes in vessel diameter observed in vaso-
motion are identified as “rhythms”, whereas the
magnitude of the diameter oscillations is referred to
as “amplitude” of vasomotion.
The rhythms of vasomotion exhibit different char-
acteristics in different tissues of the body, and are
characterized by different temporal patterns.
The rhythms in vasomotion can be highly
regular—nearly following a periodic sinusoidal wave
(see for example [6, 8, 86, 150])—or characterized
by higher complexity [3, 54, 151]. With increasing
complexity, these rhythms tend to lose their peri-
odic nature and approach a chaotic behavior, which is
thought to reflect the limit beyond which vasomotion
fails [17].
In [152], vasomotion was studied as a function of
arteriolar diameter. Arterioles with baseline diameter
in the range 50–100 m showed rhythmic oscilla-
tions at rates of 2–3 cycles/min, and magnitude of
10–20%. Rate and magnitude were found to increase
with decreasing vessel diameter, exhibiting oscillation
rates of 10–25 cycles/min in terminal arterioles.
Vasomotion is also dependent on the intravascular
pressure. In both isolated pressurized rat cerebral arter-
ies and in vivo measurements from rat basilar artery, the
amplitude of vasomotion has been shown to decrease
(and frequency to increase) with increasing pressure
[62, 82]. This finding supports the idea of vasomotion
as a protective mechanism, which potentiates cerebral
autoregulation in the lower blood pressure range, a
condition in which maintaining adequate cerebral per-
fusion becomes critical [5].
A neurogenic component of vasomotion, manifest-
ing at low frequencies (between 20 and 40–60 mHz,
approximately corresponding to 1–4 cycles/min) has
also been reported [16, 153].
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Cerebrovascular reactivity and vasomotion
In normal conditions, resistance vessels in the vascu-
lar system dilate or constrict in response to exogenous
stimuli. This can be seen as the ability of blood
flow regulation to respond to hemodynamic challenges
beyond the resting conditions. This phenomenon is dis-
tinct from the vascular response to changes in blood
pressure (autoregulation) [154].
Hypercapnic stimuli such as breath holding [155],
increased inspiratory concentration of carbon dioxide
[156], and acetazolamide administration [157], induce
a hyperemic response which causes resistance vessels
to dilate [158]. This response is thought to be mediated
by increased pH, activation of K+ channels endothelial
hyperpolarization and subsequent [Ca2+]i decrease in
vascular smooth muscle cells, and increased NO syn-
thesis by endothelial cells or neurons [154].
When cerebral vessels are already dilated to com-
pensate for a pathological reduction in cerebral
perfusion pressure, the above vasodilating stimuli may
become ineffective. The ability of blood vessels to
dilate further in response to a dilatory stimulus (or,
conversely, constrict in response to vasoconstrictor
stimuli) is referred to as cerebrovascular “reactivity”
(CVR) or “reserve” [157, 154] (also termed “cerebral
vasomotor reactivity”). The vasodilatory reserve has
been studied more extensively than the vasoconstric-
tor reserve, as noninvasive capnic stimuli evoke the
former with greater magnitude [154].
Measuring CVR can help identify patients with
reduced cerebral perfusion pressure, such as caused by
occlusive lesions of the brain-supplying arteries [157,
159, 160]. CVR in middle cerebral arteries has been
reported to predict cerebral ischemia (stroke and tran-
sient ischemic attack) in patients with carotid occlusion
[160–162] and asymptomatic carotid stenosis [160].
Reduced CVR has also been observed in AD patients
[163, 164] and has been associated with cognitive
decline [165].
Impaired cerebral vasoreactivity, namely the inabil-
ity of dilated vessels to dilate further in response
to vasodilatory stimuli, could also reduce or sup-
press vasomotion. Indeed, in conditions of pronounced
vasodilatation such as observed in functional hyper-
emia [106] or the administration of nitroglycerin [82],
vasomotion is suppressed. Furthermore, depressed
CVR occurring in conditions of chronically low per-
fusion pressure may be accompanied by impaired
vasomotion as an indirect effect of the insufficient O2
supply which alters the metabolism of vascular cells,
impairing intracellular Ca2+ dynamics [166].
In light of the above, the observation of impaired
vasoreactivity in CAA [133, 167, 168] suggests a
potential indirect implication of CAA in vasomotion
disruption.
Evaluation of cerebrovascular reactivity in AD by
Doppler ultrasonography
CVR can be indirectly and noninvasively assessed
by TCD. This method is used to measure changes in
blood flow velocity in selected cerebral arteries (e.g.,
the middle or the posterior cerebral artery) as surro-
gate of the changes in CBF [157, 160]. Assuming that
the vessel diameter remains nearly constant during the
administration of the hypercapnic stimulus, the change
in blood flow velocity measured by TCD reflects the
change in CBF in response to the stimulus. Using this
technique, observations of impaired autoregulation and
vascular reactivity in transgenic mouse models of CAA
have been confirmed in AD patients [158, 163–165,
169] and extended to vascular dementia [170]. Bär
and colleagues [158] have shown that a possible cause
of CVR impairment in AD might be cholinergic defi-
ciency (a condition which has been reported in AD
[171–173]), as the administration of galantamine (a
substance with acetylcholinesterase inhibitor proper-
ties) increased CVR in their cohort. As vasomotion
has been suggested to contain a neurogenic compo-
nent, cholinergic deficiency might also affect (dampen)
vasomotion, due to the cholinergic intrinsic innervation
of parenchymal cerebral arteries.
A reduced CVR has also been shown to predict
a worse Mini-Mental State Examination score at 12
months follow-up in AD patients with severe internal
carotid artery stenosis [174], suggesting that impaired
vasoregulation may be indicative of faster progression
of cognitive decline in AD. Buratti and colleagues
[175] found CVR depression in AD patients to be
associated with the presence of obstructive sleep apnea.
CVR has also been reported to be reduced in CAA
patients with a history of CAA-related hemorrhages
[169].
Evaluation of cerebrovascular reactivity in AD by
SPECT
Imaging of regional CBF with SPECT has been
used in the quantitative assessment of cerebrovascu-
lar deficits [154] in various conditions including AD
[41–44, 176–180]. Owing to the associated costs and
complexity, this technique has been used in a limited
number of studies compared to TCD, in the assessment
of CVR. Vascular activation in response to acetazo-
lamide (hypercapnic stimulus) has been investigated in
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AD patients [177–179]. However, in [177] and [179],
direct comparisons between AD patients and a control
group were not reported, preventing the inference of
CVR impairment in AD. In [178], CVR was reduced
in AD patients compared with controls, and CVR cor-
related with Mini-Mental State Examination score in
the AD group. Pavics and colleagues [180] assessed the
ability of CVR response to acetazolamide in discrimi-
nating AD from vascular dementia by SPECT analysis
of regional CBF. The majority (73%) of AD patients
(n = 33) showed no CVR alteration compared to pre-
injection baseline. However, comparative results with
respect to the control group were not reported.
In summary, SPECT studies have not shown sub-
stantial evidence of CVR impairment in AD [154].
Experimental approaches for measuring
vasomotion: Challenges and future perspective
Due to the intrinsic difficulty in measuring vaso-
motion, most of the data are based either on in vitro
experiments of isolated arteries, or in vivo experiments
on anesthetized animals (typically rat, hamster, or
rabbit).
While in vitro approaches provide for the most pre-
cise measurement of the arteriole diameter changes
which underpin vasomotion, insights are limited
because of the lack of natural perfusion and non-
physiological neurochemical environment. The use of
anesthesia within in vivo studies is also problematic
because of the complex and varied effects of anes-
thetic agents upon physiological, cerebrovascular, and
neurovascular function [181].
Furthermore, as the measurement of vasomotion in
the strict sense (i.e., modulation of the vessel diam-
eter) requires complex experimental settings, many
studies rely on flowmotion (i.e., modulation of blood
flow velocity) as a surrogate measure. Although the
two quantities are related, they are distinct as blood
flow velocity can change without significant changes
in vessel diameter.
The advances in optical techniques have now intro-
duced a new perspective for noninvasive hemodynamic
measurements in vivo, and in awake state [181, 182].
Advanced spectroscopic techniques (the reader is
referred to [183, 184] for review) provide quantitative
measurements of dynamic changes not only of ves-
sel diameter, but also of blood volume, blood flow, and
tissue oxygenation. Multi-photon microscopy methods
can additionally be used to probe the specific cellular
drivers of vasomotion and the mechanisms by which
structural or biochemical changes can impact upon
vasomotion as well as other aspects of cerebrovas-
cular or neurovascular function [182, 185]. Important
advances in the understanding of the role of vasomo-
tion may now arise as these techniques are applied to
study vasomotion in the increasingly wide range of
animal models of AD and/or CAA.
In light of the literature reviewed in this study, some
specific hypotheses could be tested using these models
and in vivo quantitative imaging techniques:
H1) Vasomotion is present in tortuous vascular beds.
The magnitude of vasomotion oscillations exhibits
an inverse-U shaped relationship with respect to the
degree of tortuosity.
H2) Vasomotion oscillations are driven differ-
entially according to cell type. Cellular resolution
in-vivo microscopy techniques could be used to bet-
ter delineate the endothelial, neurogenic or myogenic
contributors to concurrently measured vasomotion
oscillations.
H3) Depressed cerebrovascular reactivity is asso-
ciated with reduced vasomotion (both magnitude and
frequency of oscillations). Cerebrovascular reactivity
could be measured (and manipulated) in vivo and
relationships to specific sources of vasomotion char-
acterized.
H4) Vasomotion is depressed in diabetes and in
hypertension. Multimodal imaging methods (such as
optical spectroscopy and multiphoton imaging) could
be applied to investigate vasomotion oscillations in
animal models of these conditions.
IMPAIRED CEREBRAL VASOMOTION
IN AD
Possible pathways affecting vasomotion in
AD/CAA (Question 1)
The available data suggest that impaired vasomotion
may be implicated in the development or progression
of AD/CAA. Different pathways can be hypothesized,
as illustrated in Fig. 1.
Path A: ET-1-induced vasoconstriction depresses
vasomotion
Endothelin-1 (ET-1) is a potent vasoconstrictor pro-
duced predominantly by vascular endothelial cells
[186]. ET-1 is generated from its inactive precursor
through cleavage by endothelin converting enzyme
(ECE)-1 or ECE-2 [187]. The former is expressed in
endothelial cells, in neurons and astrocytes [188], and
in smooth muscle cells [189].
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Fig. 1. Hypothetic pathways of impaired vasomotion Path A: A upregulates ET-1 causing vasoconstriction and cessation of vasomotion.
Path B: A reduces endothelial NO synthesis. According to most studies, this promotes vasomotion (protective). However, exposure to the
vasoconstrictor thromboxane (TXA2) could increase vascular susceptibility to chaotic vasomotion. Path C: A induces ER stress in endothelial
cells and astrocytes, resulting in impaired calcium (Ca2+) homeostasis. A also interacts with vascular smooth muscle cells dysregulating
vascular tone. Mitochondrial dysfunction disrupts Ca2+ homeostasis by reducing ATP production and impairing ATP-mediated transport.
Cholinergic deficit aggravates CVR depression and vasomotion, resulting in regional CBF dysregulation, which in turn leads to hypoperfusion
and subsequent oxidative stress and A accumulation. Dotted lines indicate “feed-back” loops triggering vicious circles. Gray (white) rectangles
indicate status (process). CBF, cerebral blood flow; CVR, cerebrovascular reactivity; EC, endothelial cell; ER, endoplasmic reticulum; ET-1,
endothelin-1; NO, nitric oxide; VSMC, vascular smooth muscle cells.
Substantial evidence suggests that the upregulation
of ET-1 observed in AD, both in the cerebral cor-
tex [186, 190] and in cerebral blood vessels [191,
192], is caused by the accumulation of A [186, 187,
192–194].
ET-1 causes contraction of vascular smooth muscle
cells by multiple signaling pathways [195], including,
among others, the PLC/IP3 cascade. IP3 in turn stim-
ulates endoplasmic reticulum (ER) release of Ca2+,
and protein kinase C activation, ultimately resulting in
myosin light chain phosphatase inhibition and conse-
quent cell contraction.
The vasoconstriction caused by upregulated ET-1
could attenuate the amplitude of vasomotion [196]
or inhibit it. This is consistent with a mathematical
model of vasomotion [197] in which smooth muscle
cells exhibited synchronous [Ca2+]i oscillations and
vasomotion at intermediate [Ca2+]i, shifting to tonic
contractions and vasomotion suppression at greater
[Ca2+]i.
Path B: Reduced endothelial NO production may
promote rhythmic vasomotion (protective) or
chaotic vasomotion (detrimental)
A-endothelium interaction causes decreased NO
production [198, 199]. According to most experimen-
tal evidence, NO inhibition promotes vasomotion [8,
17, 92–95], which could be interpreted as a protective
effect potentiating cerebral perfusion and O2 delivery.
However, administration of the thromboxane TXA2
analog U46619 has been shown to elicit irregu-
lar/chaotic vasomotion in middle cerebral arteries
pre-conditioned with L-NA-induced NO blockade
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[17]. As TXA2 production (by activated platelets) is
enhanced in AD [200], and L-NA mimics the effect of
A-induced endothelial NO synthesis inhibition, the
above report suggests a plausible pathway for vaso-
motion disruption in AD.
Endothelial NO synthesis could also be reduced in
tortuous vessels as a consequence of reduced shear-
stress [149] caused by disturbed blood flow [146–148].
Path C: Altered Ca2+ homeostasis dysregulates
vasomotion
Multiple factors can influence and impair intra-
cellular Ca2+ homeostasis in the vascular wall and
astrocytes. A accumulation, mitochondrial dysfunc-
tion and oxidative stress have both individual and
combined effects on Ca2+ homeostasis.
A has been shown to interact with the ER in the
endothelial cytosol. Incubation of rat brain endothe-
lial cells with A1-40 increased ER stress-induced
unfolded protein response, transfer of Ca2+ from ER
to mitochondria [201], and affected cytosolic Ca2+
homeostasis [202].
Mitochondrial dysfunction
Intracellular Ca2+ dynamics are also susceptible
to mitochondrial dysfunction and damage, a condi-
tion that has been consistently reported in regions
of cerebrovascular lesions of the AD brain [142,
203–207], in endothelial and parenchymal cells. Mito-
chondrial dysfunction depletes cellular ATP [208],
impairing ATP-dependent transport such as the sodium
(Na+/K+-ATPase) and the calcium (Ca2+-ATPase)
pump [26, 209], and ATP-binding cassette (ABC)
transporters [26]. Of note, the latter include A trans-
porters which are responsible for A clearance from
the brain parenchyma [210, 211], in particular mul-
tidrug resistance-associated protein 1 (ABCC1) [212,
213] and ABC subfamily B member 1 (ABCB1)
[214–216].
As mitochondrial dysfunction may itself result from
A cytotoxic effects [141, 217–220], a detrimental
bidirectional link exists between A accumulation and
mitochondrial dysfunction/damage.
Mitochondrial dysfunction is further exacerbated by
oxidative stress subsequent to chronic cerebral hypop-
erfusion [142, 207, 221].
Membrane potential-related dysregulation of
vascular tone
Impaired ATPase pump function in mitochon-
drial dysfunction results in dysregulation of mem-
brane potential and consequent further alteration of
intracellular Ca2+ dynamics, which in turn affects
endothelial NO synthase activity [222], and NO-
mediated vasodilatation.
A further element of membrane potential dysregula-
tion is the effect of oxidative stress on K+ channels in
vascular smooth muscle cells. These channels play an
important role in the regulation of the membrane poten-
tial and the contractile tone of arterial smooth muscle
cells [223]. Among the different types of K+ channels,
the ATP-dependent K+ channels (KATP) have consis-
tently been found to mediate vasodilatation [224–227],
and their function has been shown to decrease in
pathological conditions such as diabetes [228] and
ischemia [229].
A substantial body of evidence suggests that oxida-
tive stress modulates the vascular vasomotor function
through K+ channel activity [230]. In vascular smooth
muscle cells of the brain, the activity of KATP appears to
be selectively modulated by different reactive oxygen
species, such as superoxide, hydrogen peroxide, and
peroxynitrite [230]. As oxidative stress manifests early
in the development of AD/CAA [24, 49, 138–140], it
is plausible that K+ channel activity and vasodilata-
tion are also impaired from the early stages, potentially
altering the rhythmic contractions of vasomotion.
Astrocyte-related dysregulation of vascular tone
Astrocytes are thought to participate in the regula-
tion of vascular tone. A has been shown to alter Ca2+
homeostasis and signaling in astrocytes [231–238],
potentially affecting neurovascular coupling and vas-
cular tone regulation, in AD/CAA.
Exposure to exogenous A has been reported to
affect astrocytic Ca2+ dynamics giving rise to fast
[Ca2+]i transients and oscillations [239]. A also
increased the expression of key components of Ca2+
signaling such as the glutamate receptor mGluR5 and
IP3 receptor-1 [240] leading to increased [Ca2+]i. A-
induced [Ca2+]i elevation has also been attributed to
Ca2+-influx pathways [234, 235] and ER stress [233].
Consistent results showing Ca2+ elevation in astro-
cytes exposed to A have been reported also in other
studies [232, 237, 238].
Other cytotoxic effects of A have been observed
in astrocytes in vitro, which could disrupt neurovas-
cular coupling. Exposure of cultured rat hippocampal
astrocytes to oligomeric A1-42, reduced the pro-
duction of the potent vasodilator EET [241]. A
also induced mitochondrial dysfunction and oxidative
stress in a Ca2+-dependent manner [235, 236]. Injec-
tion of A1-42 into mouse neocortical pyramidal cells
blocked BK channels [242]. In cultured hippocampal
astrocytes, exogenous A1-40 enhanced the expression
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of the non-selective cation channel TRPV4, resulting
in increased [Ca2+]i [243].
Taken together these data suggest that the cytotoxic
effects of A may locally de-couple neuronal activ-
ity (metabolic demand) from CBF (metabolic supply),
with detrimental effects on neuronal function.
Indeed, A may induce astrocyte-mediated dysreg-
ulation of local CBF by impairing vasodilatation (due
to reduced EET production) and/or enhancing vaso-
constriction (due to increased production of reactive
oxygen species, or inhibition of astrocytic BK chan-
nels). These indirect effects on vascular tone regulation
could add to the direct effects of A on vascular smooth
muscle cells [125, 134] and endothelial cells [140, 186,
192, 207], resulting in the alteration of Ca2+ oscilla-
tions in smooth muscle cells, which are essential to
vasomotion.
Impaired CVR and vasomotion mediate
cholinergic deficit-induced dysregulation of
regional CBF
Cholinergic deficit has been shown in AD [154,
171–173] and implicated in CVR impairment. As
the frequency spectrum of vasomotion has been sug-
gested to contain a neurogenic component in the low
frequency range [16, 153], it is plausible that the
cholinergic deficit depresses not only vascular reactiv-
ity but also vasomotion (in the slow oscillations range).
Both effects would then aggravate regional disruption
of CBF.
Impaired vasomotion as a potential mediator of
detrimental vicious circles precipitating
neurovascular damage
The dysregulation of ABC transporters caused by
mitochondrial dysfunction impairs A clearance from
the perivascular space [26, 244], resulting in A
accumulation [245]. This in turn causes mitochon-
drial dysfunction [141, 217–220] in a detrimental
vicious circle. A similar bidirectional relationship
exists between oxidative stress and mitochondrial dys-
function [141], which further sustains this loop.
Hypoperfusion is yet another recognized cause of
oxidative stress [221] and further A accumulation
[22]. We postulate that impaired vasomotion (either
low amplitude or chaotic) might contribute to this
vicious exacerbation of neurovascular damage, by two
independent pathways: by reducing peripheral perfu-
sion, and by reducing the driving force to perivascular
drainage, thus facilitating further parenchymal and
perivascular accumulation of A.
Vasomotion and the perivascular/glymphatic
clearance of Aβ (Question 2)
In the current view, vasomotion in cerebral arteries
manifests in the form of synchronous contractions of
the vessel wall [6–8]. However, some evidence from
in vivo studies on vasomotion in rat cerebral arteries
[82] and hamster skin fold [246], suggests that vasomo-
tion may also propagate longitudinally along the blood
vessel wall, following either directions with respect to
blood flow (either upstream or downstream).
The perivascular pathway proposed by Weller and
colleagues [77–79] suggests that interstitial solutes
(including A) enter the basement membranes of
blood-brain barrier capillaries and drain along the
basement membrane of the arterial tunica media, in
opposite direction to blood flow.
Based on the evidence that vasomotion can prop-
agate upstream along the vessel wall, the rhythmic
oscillations of vasomotion could contribute to the driv-
ing force of the perivascular drainage in the path
described by Weller and colleagues.
Furthermore, the rhythmic oscillations of the arterial
wall can also be viewed as a source of pressure waves
exerted on the surrounding fluid in the paravascular
space. According to the power-law attenuation of lon-
gitudinally propagating waves [247], higher frequency
waves reach shorter distances than lower frequencies
waves. Thus, the oscillations produced by vasomotion,
which are lower in frequency than those induced by
the systolic pulse, could facilitate the propulsion of
cerebrospinal fluid from the perivascular space into the
brain parenchyma, allowing deeper penetration into the
latter.
In this view, the impairment of vasomotion would
decrease the efficiency of both the perivascular and
glymphatic clearance of A, facilitating the accumu-
lation of the toxic peptide. This, in turn, would cause
further endothelial dysfunction [198], oxidative stress
[248], and decreased NO production [198]. These con-
ditions could further dampen vasomotion [17] (Fig. 1),
in a detrimental vicious circle which would accelerate
neurovascular damage.
CONCLUDING REMARKS
This study has reviewed the current literature on
cerebral vasomotion and identified potential pathways
of vasomotion impairment in AD/CAA (Fig. 1).
A cytotoxicity affects Ca2+ homeostasis in the
neurovascular unit, resulting in vascular tone dysregu-
lation. A also reduces endothelial NO synthesis and
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upregulates the potent vasoconstrictor ET-1. Impaired
vasodilatation and paradoxical vasoconstriction may
cooperate in the disruption of vasomotion, resulting in
weakened autoregulation, chronic hypoperfusion, and
reduced driving force to the perivascular/glymphatic
clearance of A. These effects in turn facilitate A
accumulation in a detrimental vicious circle.
As vascular dysfunction is thought to occur years
or even decades ahead of the clinical manifestation
of AD, quantitative measurements of cerebral vaso-
motion could predict microvascular dysfunction at an
early stage of the disease, and contribute to assess the
efficiency of therapeutic interventions. Detailed phys-
iological measurements in animal models as well as
advances in computational modeling approaches will
be important components of future research.
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Sau A, Patrono C, Davì G (2007) Determinants of platelet
activation in Alzheimer’s disease. Neurobiol Aging 28,
336-342.
[201] Fonseca ACRG, Ferreiro E, Oliveira CR, Cardoso SM,
Pereira CF (2013) Activation of the endoplasmic reticulum
stress response by the amyloid-beta 1-40 peptide in brain
endothelial cells. Biochim Biophys Acta 1832, 2191-2203.
[202] Fonseca ACRG, Moreira PI, Oliveira CR, Cardoso SM, Pin-
ton P, Pereira CF (2014) Amyloid-beta disrupts calcium and
redox homeostasis in brain endothelial cells. Mol Neurobiol.
doi: 10.1007/s12035-014-8740-7
[203] Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich
ME, Morales L (2009) Brain mitochondria as a primary tar-
get in the development of treatment strategies for Alzheimer
disease. Int J Biochem Cell Biol 41, 1989-2004.
[204] Claudio L (1996) Ultrastructural features of the blood-brain
barrier in biopsy tissue from Alzheimer’s disease patients.
Acta Neuropathol 91, 6-14.
[205] Stewart PA, Hayakawa K, Akers MA, Vinters HV (1992)
A morphometric study of the blood-brain barrier in
Alzheimer’s disease. Lab Invest 67, 734-742.
[206] Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL,
Vinters HV, Head E, Perry G, Lamanna JC, Friedland RP,
Cotman CW (2002) Atherosclerotic lesions and mitochon-
dria DNA deletions in brain microvessels as a central target
for the development of human AD and AD-like pathology
in aged transgenic mice. Ann N Y Acad Sci 977, 45-64.
[207] Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry
G (2003) Role of vascular hypoperfusion-induced oxida-
tive stress and mitochondria failure in the pathogenesis of
Azheimer disease. Neurotox Res 5, 491-504.
[208] Grammas P, Martinez J, Miller B (2011) Cerebral
microvascular endothelium and the pathogenesis of neu-
rodegenerative diseases. Expert Rev Mol Med 13, e19.
[209] De Bock M, Wang N, Decrock E, Bol M, Gadicherla
AK, Culot M, Cecchelli R, Bultynck G, Leybaert L
(2013) Endothelial calcium dynamics, connexin channels
and blood-brain barrier function. Prog Neurobiol 108,
1-20.
[210] ElAli A, Hermann DM (2011) ATP-binding cassette trans-
porters and their roles in protecting the brain. Neuroscientist
17, 423-436.
[211] Ueno M, Nakagawa T, Wu B, Onodera M, Huang C-L,
Kusaka T, Araki N, Sakamoto H (2010) Transporters in the
brain endothelial barrier. Curr Med Chem 17, 1125-1138.
[212] Abuznait AH, Kaddoumi A (2012) Role of ABC transporters
in the pathogenesis of Alzheimer’s disease. ACS Chem Neu-
rosci 3, 820-831.
[213] Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J,
Steffen J, Schumacher T, Brüning T, Plath A-S, Alfen F,
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Cavaliere F, Rodríguez JJ, Verkhratsky A, Matute C (2013)
Ca(2+) -dependent endoplasmic reticulum stress correlates
with astrogliosis in oligomeric amyloid -treated astrocytes
and in a model of Alzheimer’s disease. Aging Cell 12,
292-302.
[234] Chow S-K, Yu D, Macdonald CL, Buibas M, Silva GA
(2010) Amyloid -peptide directly induces spontaneous cal-
cium transients, delayed intercellular calcium waves and
gliosis in rat cortical astrocytes. ASN Neuro 2, e00026.
[235] Abramov AY, Canevari L, Duchen MR (2003) Changes in
intracellular calcium and glutathione in astrocytes as the
primary mechanism of amyloid neurotoxicity. J Neurosci
23, 5088-5095.
[236] Abramov AY, Canevari L, Duchen MR (2004) Calcium sig-
nals induced by amyloid beta peptide and their consequences
in neurons and astrocytes in culture. Biochim Biophys Acta
1742, 81-87.
[237] Haughey NJ, Mattson MP (2003) Alzheimer’s amyloid
beta-peptide enhances ATP/gap junction-mediated calcium-
wave propagation in astrocytes. Neuromolecular Med 3,
173-180.
[238] Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aron-
ica E, Genazzani AA (2013) Amyloid beta deregulates
astroglial mGluR5-mediated calcium signaling via cal-
cineurin and Nf-kB. Glia 61, 1134-1145.
[239] Lim D, Ronco V, Grolla AA, Verkhratsky A, Genazzani AA
(2014) Glial calcium signalling in Alzheimer’s disease. Rev
Physiol Biochem Pharmacol 167, 45-65.
[240] Grolla AA, Fakhfouri G, Balzaretti G, Marcello E, Gardoni
F, Canonico PL, DiLuca M, Genazzani AA, Lim D (2013)
A leads to Ca2+ signaling alterations and transcriptional
changes in glial cells. Neurobiol Aging 34, 511-522.
[241] Sarkar P, Narayanan J, Harder DR (2011) Differential effect
of amyloid  on the cytochrome P450 epoxygenase activity
in rat brain. Neuroscience 194, 241-249.
[242] Yamamoto K, Ueta Y, Wang L, Yamamoto R, Inoue N,
Inokuchi K, Aiba A, Yonekura H, Kato N (2011) Sup-
pression of a neocortical potassium channel activity by
intracellular amyloid- and its rescue with Homer1a. J Neu-
rosci 31, 11100-11109.
[243] Bai J-Z, Lipski J (2014) Involvement of TRPV4 channels
in A(40)-induced hippocampal cell death and astrocytic
Ca(2+) signalling. Neurotoxicology 41, 64-72.
[244] Weller RO, Massey A, Newman TA, Hutchings M, Kuo
YM, Roher AE (1998) Cerebral amyloid angiopathy: Amy-
loid beta accumulates in putative interstitial fluid drainage
pathways in Alzheimer’s disease. Am J Pathol 153, 725-733.
[245] Weller RO, Nicoll JA (2003) Cerebral amyloid angiopathy:
Pathogenesis and effects on the ageing and Alzheimer brain.
Neurol Res 25, 611-616.
[246] Colantuoni A, Bertuglia S, Intaglietta M (1985) Variations
of rhythmic diameter changes at the arterial microvascular
bifurcations. Pflugers Arch 403, 289-295.
[247] Szabo T, Wu J (2000) A model for longitudinal and shear
wave propagation in viscoelastic media. J Acoust Soc Am
107, 2437-2446.
[248] Bamji-Mirza M, Callaghan D, Najem D, Shen S, Hasim
MS, Yang Z, Zhang W (2014) Stimulation of insulin signal-
ing and inhibition of JNK-AP1 activation protect cells from
amyloid--induced signaling dysregulation and inflamma-
tory response. J Alzheimers Dis 40, 105-122.
